ReviewBiochimica et biophysica acta. Proteins and proteomics2020
Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders.
Review in Biochimica et biophysica acta. Proteins and proteomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 163 citations in OpenAlex.
- A meta-analysis of RNA-Seq studies to identify novel genes that regulate aging.Experimental gerontology · 2023Pooled it
- Pooled it
- The role of lysosome-dependent cell death in cancer.Apoptosis : an international journal on programmed cell death · 2026Review
- E3 Ubiquitin Ligase NEDD4-Mediated CTSB Ubiquitination Prevents Microglial Ferroptosis After Subarachnoid Hemorrhage.Journal of biochemical and molecular toxicology · 2026Article
- Lack of cathepsin B increases severity in Niemann-Pick disease, type C1 mice.Neuroscience letters · 2026Article
- Integrative single-cell and spatial transcriptomics combined with machine learning to discover complement-associated biomarkers in temporal lobe epilepsy with hippocampal sclerosis.Functional & integrative genomics · 2026Article
- The landscape of plasma proteomic links to human organ imaging.Nature communications · 2026Article
- Gaining Insights Into the Formation of the Cathepsin B Inhibitor II-Human Serum Albumin Complex: A Multidisciplinary Approach.Luminescence : the journal of biological and chemical luminescence · 2026Article
- Association of Cathepsin Proteins with Alzheimer's Disease Risk: An Integrated Observational and Genetic Analysis.Neuromolecular medicine · 2026Observational
- Muscle-brain crosstalk as a driver of brain health in aging.GeroScience · 2026Review
- Bidirectional causal association between cathepsins and neuropsychiatric disorders: univariate and multivariate Mendelian randomization study.European archives of psychiatry and clinical neuroscience · 2026Article
- Targeting cathepsin B activity by natural inhibitors: a structural dynamics and network pharmacology approach for amyloid-beta dysregulation in Alzheimer's disease.Molecular diversity · 2026Article
- Light and Enzymatic Cooperative Response in Supramolecular Fibers: A Synergistic Strategy for Potential Drug Delivery Applications.Biomacromolecules · 2026Article
- Multiomics Profiling Supports Cathepsin B as a Protective Factor in Cerebral Small Vessel Disease.Research square · 2026Article
- Morphable 'Stitched' Sensors for Simultaneous Spatiotemporal Tracking of Correlated Bioanalytes in Living Cells.JACS Au · 2026Article
- Microglial cathepsin B is necessary for neuronal efferocytosis in zebrafish and mice during brain development.Nature communications · 2026Article
- Exercise alleviates cognitive dysfunction in Alzheimer's disease mice via skeletal muscle-derived extracellular vesicles that enhance plaque clearance by microglia.Nature aging · 2026Article
- Oral Dysbiosis and Neuroinflammation: Implications for Alzheimer's, Parkinson's and Mood Disorders.Microorganisms · 2026Review
- Therapeutic potential of exerkines in neurodegenerative and mental disorders: a narrative review.Frontiers in physiology · 2026Review
- Fibronectin type III domain-containing protein 5/irisin in extracellular vesicles is reduced in older individuals.Brain communications · 2026Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Investigations of Alzheimer's disease (AD), traumatic brain injury (TBI), and related brain disorders have provided extensive evidence for involvement of cathepsin B, a lysosomal cysteine protease, in mediating the behavioral deficits and neuropathology of these neurodegenerative diseases. This review integrates findings of cathepsin B regulation in clinical biomarker studies, animal model genetic and inhibitor evaluations, structural studies, and lysosomal cell biological mechanisms in AD, TBI, and related brain disorders. The results together indicate the role of cathepsin B in the behavioral deficits and neuropathology of these disorders. Lysosomal leakage occurs in AD and TBI, and related neurodegeneration, which leads to the hypothesis that cathepsin B is redistributed from the lysosome to the cytosol where it initiates cell death and inflammation processes associated with neurodegeneration. These results together implicate cathepsin B as a major contributor to these neuropathological changes and behavioral deficits. These findings support the investigation of cathepsin B as a potential drug target for therapeutic discovery and treatment of AD, TBI, and TBI-related brain disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.